Please use this identifier to cite or link to this item:
https://doi.org/10.1177/0091270011407195
DC Field | Value | |
---|---|---|
dc.title | Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants | |
dc.contributor.author | Willis, B.A. | |
dc.contributor.author | Zhang, W. | |
dc.contributor.author | Ayan-Oshodi, M. | |
dc.contributor.author | Lowe, S.L. | |
dc.contributor.author | Annes, W.F. | |
dc.contributor.author | Sirois, P.J. | |
dc.contributor.author | Friedrich, S. | |
dc.contributor.author | De La Peña, A. | |
dc.date.accessioned | 2014-11-28T02:52:49Z | |
dc.date.available | 2014-11-28T02:52:49Z | |
dc.date.issued | 2012-06 | |
dc.identifier.citation | Willis, B.A., Zhang, W., Ayan-Oshodi, M., Lowe, S.L., Annes, W.F., Sirois, P.J., Friedrich, S., De La Peña, A. (2012-06). Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants. Journal of Clinical Pharmacology 52 (6) : 904-913. ScholarBank@NUS Repository. https://doi.org/10.1177/0091270011407195 | |
dc.identifier.issn | 00912700 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/112067 | |
dc.description.abstract | Semagacestat, γ-secretase inhibitor, reduces formation of amyloid beta peptide. Two single-dose (140 mg), openlabel, randomized, 3-period, crossover studies evaluated the effect of formulation, food, and time of dosing on the pharmacokinetics and pharmacodynamics of semagacestat in healthy participants. The first study (n = 14) compared tablet to capsules. For all formulations, the median time to maximum plasma concentration (tmax) was generally 1.0 hour. Plasma elimination was rapid, with a half-life of approximately 2.5 hours. Tablet form II bioavailability (F) relative to capsule was approximately 100% (F = 1.03 [90% confidence interval (CI), 0.96-1.10]). In the second study, participants (n = 27) received semagacestat either fed or fasting in the morning or fasting in the evening. No significant change in exposure (AUC0-8 [area under the concentration-time curve from 0 to infinity] ratio = 1.02, [90% CI, 0.990-1.05]) occurred with food, whereas maximum plasma concentration (Cmax) declined approximately 15%, and median tmax was delayed to 1.5 hours. Time of dosing made no significant difference in AUC0-8, Cmax, or tmax (AUC0-8 ratio 1.01, [90% CI, 0.975-1.04]). No clinically significant safety concerns occurred in either study. Accordingly, semagacestat may be dosed without regard to formulation, food, or time of administration. © 2012 The Author(s). | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1177/0091270011407195 | |
dc.source | Scopus | |
dc.subject | γ-secretase | |
dc.subject | Alzheimer disease | |
dc.subject | Semagacestat | |
dc.type | Article | |
dc.contributor.department | INSTITUTE OF MOLECULAR & CELL BIOLOGY | |
dc.description.doi | 10.1177/0091270011407195 | |
dc.description.sourcetitle | Journal of Clinical Pharmacology | |
dc.description.volume | 52 | |
dc.description.issue | 6 | |
dc.description.page | 904-913 | |
dc.description.coden | JCPCB | |
dc.identifier.isiut | 000304228900012 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.